Metabolic abnormalities linked to an increased cardiovascular risk are associated with high-grade prostate cancer: A single biopsy cohort analysis

Prostate Cancer and Prostatic Diseases

Volumn 19, Issue 1, 2016, Pages 35-39

  De Nunzio, C ^a   Truscelli, G ^b   Trucchi, A ^a   Petta, S ^a   Tubaro, M ^c   Gacci, M ^d   Gaudio, C ^b   Presicce, F ^a   Tubaro, A ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c SAN FILIPPO NERI HOSPITAL   (Italy)

^d UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HIGH DENSITY LIPOPROTEIN; PROSTATE SPECIFIC ANTIGEN; TRIACYLGLYCEROL;

AGED; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD SAMPLING; BODY MASS; CANCER GRADING; CARDIOVASCULAR RISK; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; RISK FACTOR; ADULT; BIOPSY; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; COMPLICATION; FEMALE; METABOLIC SYNDROME X; METABOLISM; MIDDLE AGED; PATHOLOGY; PROSTATE TUMOR;

ADULT; AGED; BIOPSY; BLOOD PRESSURE; BODY MASS INDEX; CARDIOVASCULAR DISEASES; COHORT STUDIES; FEMALE; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; NEOPLASM GRADING; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 84957843913     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/pcan.2015.45     Document Type: Article

References (29)

1. Berghofer A, Pischon T, Reinhold T, Apovian CM, Sharma AM, Willich SN. Obesity prevalence from a European perspective: a systematic review. BMC Public Health 2008; 8: 200-210.
2. Buschemeyer WC, Freedland SJ. Obesity and prostate cancer: epidemiology and clinical implications. Eur Urol 2007; 52: 331-343.
3. Freedland SJ, Wen J, Wuerstle M, Shah A, Lai D, Moalej B et al. Obesity is a significant risk factor for prostate cancer at the time of biopsy. Urology 2008; 72: 1102-1105.
4. Freedland SJ, Bañez LL, Sun LL, Fitzsimons NJ, Moul JW. Obese men have highergrade and larger tumors: an analysis of the duke prostate center database. Prostate Cancer Prostatic Dis 2009; 12: 259-263.
5. De Nunzio C, Aronson W, Freedland SJ, Giovannucci E, Parsons JK. The correlation between metabolic syndrome and prostatic diseases. Eur Urol 2012; 61: 560-570.
6. Esposito K, Chiodini P, Capuano A, Bellastella G, Maiorino MI, Parretta E et al. Effect of metabolic syndrome and its components on prostate cancer risk: meta-analysis. J Endocrinol Invest 2013; 36: 132-139.
7. Islami F, Moreira DM, Boffetta P, Freedland SJ. A systematic review and metaanalysis of tobacco use and prostate cancer mortality and incidence in prospective cohort studies. Eur Urol 2014; 66: 1054-1064.
8. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G et al. 2007 ESH-ESC practice guidelines for the management of arterial hypertension: ESHESC task force on the management of arterial hypertension. J Hypertens 2007; 25: 1751-1762.
9. De Nunzio C, Trucchi A, Miano R, Stoppacciaro A, Fattahi H, Cicione A et al. The number of cores positive for high grade prostatic intraepithelial neoplasia on initial biopsy is associated with prostate cancer on second biopsy. J Urol 2009; 181: 1069-1074.
10. Buse JB, Ginsberg HN, Bakris GL, Clark NG, Costa F, Eckel R et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus. Diabetes Care 2007; 30: 162-172.
11. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143-3421.
12. Serfling R, Shulman M, Thompson GL, Xiao Z, Benaim E, Roehrborn CG et al. Quantifying the impact of prostate volumes, number of biopsy cores and 5-alphareductase inhibitor therapy on the probability of prostate cancer detection using mathematical modelling. J Urol 2007; 177: 2352-2356.
13. De Nunzio C, Freedland SJ, Miano L, Finazzi Agrò E, Bañez L, Tubaro A. The uncertain relationship between obesity and prostate cancer: an Italian biopsy cohort analysis. Eur J Surg Oncol 2011; 37: 1025-1029.
14. Presti JC Jr, O'Dowd GJ, Miller MC, Mattu R, Veltri RW. Extended peripheral zone biopsy schemes increase cancer detection rates and minimize variance in prostate specific antigen and age related cancer rates: results of a community multipractice study. J Urol 2003; 169: 125-129.
15. De Nunzio C, Freedland SJ, Miano R, Trucchi A, Cantiani A, Carluccini A et al. Metabolic syndrome is associated with high grade Gleason score when prostate cancer is diagnosed on biopsy. Prostate 2011; 71: 1492-1498.
16. Bhatt DL, Steg PG, Ohman EM, Hirsch AT, Ikeda Y, Mas JL et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA 2006; 295: 180-189.
17. Lund HL, Wisloff TF, Holme I, Nafstad P. Metabolic syndrome predicts prostate cancer in a cohort of middle-aged Norwegian men followed for 27 years. Am J Epidemiol 2005; 164: 769-774.
18. Laukkanen JA, Laaksonen DE, Niskanen L, Pukkala E, Hakkarainen A, Salonen JT. Metabolic syndrome and the risk of prostate cancer in Finnish men: a populationbased study. Cancer Epidemiol Biomarkers Prev 2004; 13: 1646-1650.
19. Wallstrom W, Bjartell A, Gullberg B, Olsson H, Wirfält E. A prospective Swedish study on body size, body composition, diabetes and prostate cancer risk. Br J Cancer 2009; 100: 1799-1805.
20. Martin RM, Vatten L, Gunnell D, Romundstad P, Nilsen TI. Components of the metabolic syndrome and risk of prostate cancer: the HUNT 2 cohort, Norway. Cancer Causes Control 2009; 20: 1181-1192.
21. Tande AJ, Platz EA, Folsom AR. The metabolic syndrome is associated with reduced risk of prostate cancer. Am J Epidemiol 2006; 164: 1094-1102.
22. Beebe-Dimmer JL, Nock NL, Neslund-Dudas C, Rundle A, Bock CH, Tang D et al. Racial differences in risk of prostate cancer associated with metabolic syndrome. Urology 2009; 74: 185-190.
23. Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren M et al. European Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2012; 33: 1635-1701.
24. Mancia G. Comparing methods for assessing cardiovascular risk. J Hypertens 2009; 27: 2342-2343.
25. Sehestedt T, Jeppesen J, Hansen TW, Rasmussen S, Wachtell K, Ibsen H et al. Risk stratification with the risk chart from the European Society of Hypertension compared with SCORE in the general population. J Hypertens 2009; 27: 2351-2357.
26. De Nunzio C, Freedland SJ, Miano R, Trucchi A, Cantiani A, Carluccini A et al. Metabolic syndrome is associated with high grade Gleason score when prostate cancer is diagnosed on biopsy. Prostate 2011; 71: 1492-1498.
27. Freedland SJ, Wen J, Wuerstle M, Shah A, Lai D, Moalej B et al. Obesity is not a significant risk factor for prostate cancer at the time of biopsy. Urology 2008; 72: 1102-1105.
28. Pruthi RS, Swoeds K, Schultz H. The impact of obesity on the diagnosis of prostate cancer using a modern extended biopsy scheme. J Urol 2009; 181: 574-577.
29. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G. 2007 Guidelines for the management of arterial hypertension of the European Society of hypertension and of the European Society of Cardiology. Eur Heart J 2007; 28: 1462-1536.